You are here

Press Releases

Minneapolis, MN, June 26, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific Sessions: Pathways to Cardiovascular Therapeutics has accepted two abstracts for presentation that feature novel preclinical findings with BioSig’s PURE EP System.

SOUTH JORDAN, Utah, June 22, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it has received 513(f)(2) (de novo) classification from the FDA to expand indication for Merit’s Embosphere® Microspheres.  The indication now includes prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).

Hitachi Healthcare and the West Virginia University Heart and Vascular Institute today announced the formation of a new partnership to advance the evaluation of left ventricle (LV) mechanical function using advanced analysis tools that can provide a more comprehensive assessment of cardiovascular disease. Partho Sengupta, M.D., the Heart and Vascular Institute’s director of cardiovascular imaging, will serve as the project’s principal investigator during this multi-year strategic partnership. 

Dallas, June 6, 2017 – The American Heart Association (AHA) and The Children’s Heart Foundation (CHF) announced today the third round of recipients for the Congenital Heart Defect (CHD) Research Awards, a research program co-funded by the AHA and CHF. Five research programs were selected to receive a total of $561,798 in funding. The CHD Research Awards will fund more than $22 million in CHD-specific research through 2021. To date, more than $2.42 million has been awarded.

Premium cardiac and vascular imaging rises to a new standard as Hitachi Healthcare Americas introduces the new premium 2D and 3D cardiovascular ultrasound system, the LISENDO 880, at the American Society of Echocardiography 2017 in Baltimore, Maryland on June 3rd, 2017.

AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release) for injectable suspension, with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA 9-13 June 2017.

Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection System (CPS), via de novo classification, enabling U.S. commercialization of the device. The Sentinel is the first and only device available in the U.S. that offers protection against the risk of stroke by capturing and removing debris dislodged during transcatheter aortic valve replacement (TAVR) before it reaches the brain. In the pivotal SENTINEL randomized controlled trial, use of Sentinel reduced strokes by 63 percent in the first 72 hours after TAVR and maintained a substantial difference at 90 days.

When advanced cardiac ultrasound imaging is needed for fast and confident diagnoses, Toshiba Medical, a Canon Group company, will showcase its AplioTM i900 at this year’s American Society of Echocardiography (ASE) 2017 annual meeting in Baltimore, Md., June 2–6, 2017 (Booth #313). The Aplio i900 system is the latest addition to the premium Aplio i-series ultrasound platform, providing cardiologists and cardiovascular sonographers an ultrasound solution with excellent imaging clarity and definition.

NEW ORLEANS, La.--(BUSINESS WIRE)--Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, today announced the commercial launch in the United States of the Company’s groundbreaking DABRA™ System for the treatment of Peripheral Artery Disease.

In an effort to battle Peripheral Artery Disease (PAD), the leading cause of limb amputations, the Food and Drug Administration (FDA) announced today that it has granted market clearance to Ra Medical Systems, makers of excimer lasers and catheters for cardiovascular and dermatological diseases, for the Company’s groundbreaking DABRA System.

HOUSTON (May 30, 2017) – Digisonics (Booth #421) will exhibit its latest functionality for Cardiovascular Information Systems (CVIS) at the American Society of Echocardiography 28th Annual Scientific Sessions in Baltimore, Md.

Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2017, which ended April 28, 2017.

WARREN, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the presentation of new clinical data from a Phase 2 clinical trial that investigated INOpulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension (PH-IPF) at the American Thoracic Society (ATS) 113th International Conference, currently taking place in Washington DC.

Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels. Results from the RESOLUTE ONYX 2.0 mm Clinical Study were presented today as a Hot Line/Late-Breaking Trial Session at the 2017 EuroPCR Annual Meeting and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Intervention.

CHICAGO – With one in three American adults living with high blood pressure and at increased risk of heart attack and stroke, the American Medical Association (AMA) is joining the American Heart Association (AHA) to increase public awareness of this silent killer. In conjunction with World Hypertension Day tomorrow, the AMA is supporting the Know Your Numbers campaign to encourage more patients to monitor their blood pressure levels and take the necessary steps to get their high blood pressure—or hypertension—under control.

PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and effectiveness of a new stent to treat patients with coronary heart disease who are at higher risk for bleeding.

DUBLIN - May 10, 2017 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure. These devices also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. The Percepta(TM) Quad CRT-P MRI SureScan(TM), Serena(TM) Quad CRT-P MRI SureScan(TM) and Solara(TM) Quad CRT-P MRI SureScan(TM)are expected to be available commercially in the United States in early summer 2017.

NEW ORLEANS and MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can adversely affect stent-related outcomes. Aligned with the Boston Scientific "Close the Gap" health equity initiative, PLATINUM Diversity is a first-of-its-kind study focusing exclusively on women and minorities with coronary artery disease that is designed to shed light into the clinical, social, behavioral and economic determinants of health treatment outcome disparities in these groups.

MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. Data confirmed that the WATCHMAN device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash.

Pages